Compare · SERM
Raloxifene vs Tamoxifen
Both are serm compounds. Here's how they line up on the evidence — graded the same way.
| Raloxifene | Tamoxifen | |
|---|---|---|
| Evidence | 10/10 | 10/10 |
| Class | SERM | SERM |
| Summary | Raloxifene is a selective estrogen receptor modulator (SERM) — an FDA-approved postmenopausal osteoporosis and breast-cancer-risk-reduction drug, not a peptide. Its defining serious risks are blood clots and fatal stroke; it is banned in sport at all times (WADA S4.2). | Tamoxifen is a selective estrogen receptor modulator (SERM) — an FDA-approved breast-cancer drug with one of the strongest evidence bases in oncology, not a peptide. Anabolic-steroid users take it off-label to blunt gynecomastia and attempt testosterone 'restart,' an unstudied practice that is banned in sport (WADA S4.2) and not without real risk. |
| Full profile → | Full profile → |
Raloxifene
Raloxifene, sold as Evista, is a pill taken once a day. It belongs to a group of drugs called SERMs — selective estrogen receptor modulators (medicines that switch estrogen's effects on or off depending on which part of the body they reach). It's a legitimate, well-studied prescription drug. It…
Tamoxifen
Tamoxifen, sold as Nolvadex, is a selective estrogen receptor modulator (SERM — a drug that turns the estrogen signal up in some tissues and down in others). It is one of the most thoroughly studied drugs in all of cancer medicine. It helps to be clear about what it is and isn't: tamoxifen is not a…